Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLK-0016
- Development stage
- Preclinical
- Lead developer
- HLK Pharmacin
- Modality
- Small Molecules
01
Overview
HLK-0016 is an investigational small molecule formulation of oxymorphone being developed by Shenzhen Pharmacin for the management of pain. Developed via the 505(b)(2) regulatory pathway, HLK-0016 likely utilizes the company's proprietary SpraySol™ technology to optimize the delivery or pharmacokinetic profile of the active ingredient. Oxymorphone is a potent semi-synthetic opioid analgesic that primarily acts as an agonist at the mu-opioid receptors in the central nervous system, providing relief for moderate to severe pain. The program is currently in the early stages of development.
- Other names
- Oxymorphone formulation
02
Targets
KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on HLK-0016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLK-0016.